Oncotarget is a peer-reviewed journal famous for its constructive, punctual, insightful, and multiple reviews that assist scientists to sensitize and increase the impact of research. This journal was launched by Dr. Mikhail Blagosklonny of the Roswell Park Cancer Institute together with his colleague Andrei V. Gudkov. Dr. Blagosklonny and Mr. Gudkov are the editors of this journal. These two scholars established this journal with the objective of:
- Making scientific results readily available on a weekly basis.
- Enhance the impact of research.
- Share discoveries promptly.
- Merge different fields of medicine.
- Encourages the use of clinical and basic science to fight against diseases.
Oncotarget is managed by some of the prominent scientists in the field of oncology who help contribute to the progress of research. This journal has gained popularity in the last seven years, and this has prompted it to launch some sections beyond cancer research. These topics include cell biology, neuroscience, endocrinology, cardiology, pharmacology, and metabolism. Oncotarget publishes four main types of articles including editorial & news, reviews, research papers, and books. Read more about Oncotarget at Bioxbio.
Editorials are mainly discussions by authors about their already published articles in other journals. Onctotaget publishes these articles with conditions that they must have a word limit of 800 words and less than seven references. This journal also publishes reviews mostly about broadly discussed topics. Reviews should contain figures and at least ninety references. Research papers, on the other hand, should have no word or text limit. Oncotarget recommends that books to be published should have colored figures with a minimal number of five hundred references.
Among the chief editors of this journal is Dr. Blagosklonny who equips students at the Roswell Park Cancer Institute with oncological knowledge. He has published over 260 articles and, hence, experienced and skilled when it comes to editing research papers. His efforts have made Oncotarget be recognized as one of the most prominent journals in the United States. Mr. Gudkov is the senior VP of basic research at the Roswell Park Cancer Institute. He is an expert in molecular biology and experimental oncology. Mr. Gudkov has vested interest in gene & drug discovery and molecular targets for cancer treatment. Oncotarget is also available on Dove Press.